Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings-Reference-Cited by-同舟云学术

Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings

Published:2022-01 Issue:1 Volume:40 Page:1-2
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Grzelak Candice A.,Goddard Erica T.,Lederer Emma E.,Rajaram Kamya,Dai Jinxiang,Shor Ryann E.,Lim Andrea R.,Kim Jeanna,Beronja Slobodan,Funnell Alister P.W.,Ghajar Cyrus M.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference10 articles.

1. Transgenic mice that accept Luciferase- or GFP-expressing syngeneic tumor cells at high efficiencies;Aoyama;Genes Cells,2018

2. GFP-specific CD8 T cells enable targeted cell depletion and visualization of T-cell interactions;Agudo;Nat Biotechnol,2015

3. “Glowing head” mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts;Day;PLoS One,2014

4. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope;Gambotto;Gene Ther.,2000

5. Deletional tolerance mediated by extrathymic Aire-expressing cells;Gardner;Science,2008

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models;Pigment Cell & Melanoma Research;2024-09-10

2. HLA-E and NKG2A Mediate Resistance toM. bovisBCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer;2024-09-03

3. Leveraging preclinical models of metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Development of an optimized machine learning approach for assessing brain metastatic burden in preclinical models;2024-08-23

5. Luciferase transduction and selection protocol for reliable in vivo bioluminescent measurements in cancer research;Heliyon;2024-07